To evaluate the association of baseline and postinfusion patient characteristics with acute kidney injury (AKI) in the month after chimeric antigen receptor T-cell (CAR-T) therapy
Latest Information Update: 13 Jul 2022
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
Most Recent Events
- 13 Jul 2022 New trial record
- 01 Jul 2022 Results published in the Mayo Clinic Proceedings